ir.advaxis.comAdvaxis, Inc. Investor Center |

-- end Viewport scaling -- Our Technology Corporate Presentation Presentations and Publications Clinical Trials HPV-Associated Cancers PSA-Associated Cancers HER2-Associated Cancers MINE™ Patient Stories Partners About Us Investors News Events & Presentations Company Information Financial Information Stock Chart Corporate Governance Analyst Coverage Investor FAQ Videos Social Media Email Alerts Investor Contacts Our Technology Corporate Presentation Presentations and Publications Clinical Trials HPV-Associated Cancers PSA-Associated Cancers HER2-Associated Cancers MINE™ Patient Stories Partners About Us Investors News Events & Presentations Company Information Financial Information Stock Chart Corporate Governance Analyst Coverage Investor FAQ Videos Social Media Email Alerts Investor Contacts -- Investor Relations NASDAQ: ADXS Loading View more NASDAQ: ADXS View more Login -- FEATURED NEWS January 21, 2020 Advaxis, Inc. Announces Pricing of $10.5 Million Registered Direct Offering PRINCETON, N.J., Jan. 21, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. Read More January 7, 2020 Advaxis Announces FDA Clearance of IND for ADXS-504 for Treatment of Prostate Cancer PRINCETON, N.J., Jan. 07, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced the U.S. Read More December 20, 2019 Advaxis Reports Fiscal Year 2019 Financial Results and Provides a Business Update PRINCETON, N.J.--( BUSINESS WIRE )--Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announces its financial results for the fiscal year ended October 31, 2019 and provides a business update. Fiscal Year... Read More December 4, 2019 Advaxis to Present at 12th Annual LD Micro Main Event Investor Conference PRINCETON, N.J.--( BUSINESS WIRE )-- Advaxis, Inc. (Nasdaq: ADXS ), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that Kenneth A. Berlin, President and Chief Executive Officer will present at the upcoming LD Micro Main Event... Read More Upcoming Events No upcoming events Company Information Corporate Presentation - January 2020 Immuno-Oncology 360° Conference Presentation Recent Filings Date Form Type Form Description Download Date 01/23/2020 Form Type 8-K Form Description Current report pursuant to Section 13 or 15(d) Download Date 01/21/2020 Form Type 424B5 Form Description Prospectus [Rule 424(b)(5)] Download Date 01/21/2020 Form Type SC 13G/A Form Description [Amend] Statement of acquisition of beneficial ownership by individuals Download Date 01/21/2020 Form Type 10-K/A Form Description [Amend] Annual report [Section 13 and 15(d), not S-K Item 405] Download Date 01/16/2020 Form Type 8-K Form Description Current report pursuant to Section 13 or 15(d) Download View More Management Kenneth Berlin, J.D. PRESIDENT AND CHIEF EXECUTIVE OFFICER Robert G. Petit, Ph.D. CHAIR OF SCIENTIFIC ADVISORY BOARD Andres Gutierrez, M.D., Ph.D. EXECUTIVE VICE PRESIDENT AND CHIEF MEDICAL OFFICER Molly Henderson EXECUTIVE VICE PRESIDENT AND CHIEF FINANCIAL OFFICER View More Social Media Twitter @Advaxis Full name: Advaxis NASDAQ:ADXS 45 weeks 2 days ago - https://t.co/zNWwU2o9CE Full name: Advaxis NASDAQ:ADXS 45 weeks 2 days ago - https://t.co/YtbdivKOQJ Full name: Advaxis NASDAQ:ADXS 45 weeks 2 days ago - https://t.co/zNWwU2o9CE Full name: Advaxis NASDAQ:ADXS 48 weeks 2 days ago - Advaxis Announces Enrollment Of The First Patient In Its Phase 1/2 Trial For ADXS-HOT In The Treatment Of Non-Small… https://t.co/Liu7KnrKZq View on Twitter Facebook @advaxisinc Advaxis, Inc. Advaxis employees supporting Breast Cancer Awareness Month #wearpink about 65 weeks 3 days ago Advaxis, Inc. Advaxis to Present at the Cantor Fitzgerald Global Healthcare Conference w​w​w​.​b​u​s​i​n​e​s​s​w​i​r​e​.​c​o​m​/​n​e​w​s​/​h​o​m​e​/​2​0​1​8​0​9​2​5​0​0​5​1​8​2​/​e​n​/​A​d​v​a​x​i​s​-​P​r​e​s​e​n​t​-​C​a​n​t​o​r​-​F​i​t​z​g​e​r​a​l​d​-​G​l​o​b​a​l​-​H​e​a​l​t​h​c​a​r​e​-​C​o​n​f​e​r​e​n​c​e Advaxis to Present at the Cantor Fitzgerald Global Healthcare Conference businesswire.com about 69 weeks 2 days ago Advaxis, Inc. Advaxis Announces Pricing of Its Public Offering of Common Stock and Warrants w​w​w​.​b​u​s​i​n​e​s​s​w​i​r​e​.​c​o​m​/​n​e​w​s​/​h​o​m​e​/​2​0​1​8​0​9​0​7​0​0​5​2​4​5​/​e​n​/​A​d​v​a​x​i​s​-​A​n​n​o​u​n​c​e​s​-​P​r​i​c​i​n​g​-​P​u​b​l​i​c​-​O​f​f​e​r​i​n​g​-​C​o​m​m​o​n​-​S​t​o​c​k Advaxis Announces Pricing of Its Public Offering of Common Stock and Warrants businesswire.com about 71 weeks 6 days ago View on Facebook All Social Media Sign Up for Alerts Enter your keywords: Our Lm Technology™ Intuitive Cancer Treatment The Advaxis Difference Intellectual Property Corporate Presentation Presentations and Publications Clinical Trials HPV-Associated Cancers PSA-Associated Cancers HER2-Associated Cancers MINE™ -- NEO Program HOT Program Patient Stories Partners Clinical Partners Licensing Agreements Academic Institutions Partners About Us Our Values Leadership Board of Directors Scientific Advisory In the News Careers Upcoming Events Investors Company Information Financial Information Stock Chart SEC Filings Corporate Governance Privacy Policy Our Lm Technology™ Intuitive Cancer Treatment The Advaxis Difference Intellectual Property Corporate Presentation Presentations and Publications Clinical Trials HPV-Associated Cancers PSA-Associated Cancers HER2-Associated Cancers MINE™ -- NEO Program HOT Program Patient Stories Partners Clinical Partners Licensing Agreements Academic Institutions Partners About Us Our Values Leadership Board of Directors Scientific Advisory In the News Careers Upcoming Events Investors Company Information Financial Information Stock Chart SEC Filings Corporate Governance Copyright © 2020 All Rights Reserved Business Wire InvestorHQ sm...